What will new weight loss medicines bring to people with type 2 diabetes?
While the new generation of available weight management medications are the most effective...
Read More
Category: Uncategorized
Retatrutide hot off the presses: health benefits, treatment targets, and flexible dosing
As blogged previously, the TRIUMPH-1 study of retatrutide demonstrated previously unsurpassed...
Read More
What are the risks of losing weight too fast with weight loss medication?
In the ‘old days’ – really only up until 5 years ago! – when we had only...
Read More
Why % weight loss is unacceptable as a treatment target of weight loss medication
The target metric long required by regulatory agencies (American FDA, Health Canada, European...
Read More
Could the shingles vaccine decrease risk of heart attack, stroke, and even dementia?
About one in three adults who grew up before the chickenpox vaccine era (which started around year...
Read More
Does hand grip strength predict risk of dementia?
Sarcopenia, defined as low muscle mass with loss of strength and/or function, is associated with...
Read More
Canada’s Drug Agency recommends Zepbound for prediabetes – will this cut cost for Canadians?
Prediabetes is extremely common, affecting 14-37% of people with obesity (depending on the...
Read More
Altered skin sensation with GLP1 – could it be something other than dyesthesia?
As blogged previously, GLP-1 based medications can sometimes cause dysesthesia, meaning unusual or...
Read More
Testosterone Treatment During Weight Loss: Can your needs change?
As blogged previously, there are many medications that need to be considered for monitoring and...
Read More
FDA guides special access to retatrutide – before approval for use?
Well this is a first in the obesity world. In USA, the FDA has provided guidance to drugmaker Eli...
Read More
Is retatrutide ‘best ever’ for weight loss in type 2 diabetes?
As blogged previously, retatrutide is a GLP1, glucagon, and GIP (‘triple G’) agonist...
Read More
Is it ok to microdose GLP1 medications?
There’s a lot of chatter in the virtual space these days about microdosing GLP1 medicines...
Read More
Dr. Sue Pedersen
I am a medical doctor, Specialist in Endocrinology & Metabolism, a Diplomate of the American Board of Obesity Medicine, and a Clinical Lecturer at the University of Calgary, Canada. After completing my training as an Endocrinologist in 2005 at the University of Calgary, I have worked in Calgary, at the Royal University Hospital in Saskatchewan, and at the University of Copenhagen in Denmark. I have a busy clinical practice at C-ENDO Diabetes and Endocrinology Clinic in Calgary, caring for patients with diabetes, obesity, thyroid, and other hormone issues. I am also involved in clinical research in diabetes and obesity. I am the lead author of the 2020 and 2022 Pharmacotherapy Chapters of the Canadian Obesity Clinical Practice Guidelines, and a member of the Expert Committee for the Diabetes Canada Clinical Practice Guidelines as an author on the Weight Management chapter. I am passionate, enthusiastic, and driven to help conquer the stigma against obesity; educate health care professionals and the public about obesity and diabetes; and to help us become a healthier society!
